News
Featured Image
Abortion drug MifepristonePhil Walter/Getty Images

WASHINGTON, D.C. (LifeSiteNews) — The U.S. Food and Drug Administration (FDA) filed an update Wednesday with the U.S. District Court for the Western District of Louisiana stating that it now expects to complete its review of abortion pill safety data by March 2027 amid ongoing suspicions the effort was politically timed to avoid next month’s midterm elections.

Last fall, Louisiana sued the FDA over its removal of the requirement that abortion drugs be dispensed in-person, which drastically expanded their usage, encroached on state law, and harmed women such as co-plaintiff Rosalie Markezich. The requirement had been ended under former President Joe Biden, but President Donald Trump decided during the 2024 election campaign he would not restore it.

Under pressure from pro-lifers, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. promised in May 2025 a “complete review” of the drugs’ safety data, offering hope a policy change might follow the results. But more than a year has gone by without results, and the Trump administration has urged the court to at least temporarily deny relief to Louisiana and Markezich, arguing that they lacked legal standing and claiming that a judgment in the case would cause a “disruption” with the review.

In April, the district court had agreed to temporarily stay proceedings but ordered the federal government to provide a status update on its review within the next six months. On October 7, the FDA filed its update, which details some of the steps it has taken so far, and claims it is “on track to obtain study results by mid-December 2026. FDA will then need to review and evaluate/interpret the results and draft a report. FDA expects to complete that process not later than March 2027. The agency also plans to complete its TreeScan analysis in the same time frame.”

After completing the study and its review of the Risk Evaluation and Mitigation Strategies (REMS) for mifepristone, it says, “FDA will decide whether changes to the Mifepristone REMS Program are necessary and, if applicable, initiate any such changes in accordance with established processes. FDA anticipates that it will be able to provide an update to its estimated date of completion as more information becomes known, particularly in March 2027 when it expects to complete its report on the final study results.”

The prognosis came just days after the White House denied a new report that administration officials directed the Justice Department to “move slowly on any abortion-related actions” because an “aggressive approach on abortion would generate unwanted attention” in a tough political season for the GOP.

“Even if the agency were to find that mifepristone safety review concludes that they needed to return safeguards, they still would have to go through an administrative process, and the earliest that we would see relief would be the end of 2027-2028 at this point, and that does nothing to alleviate or fix or cure the lawfulness of the 2023 REMS decision – that’s the thing that we’re actually litigating in court – no matter what they find in this study, that decision in 2023 by the FDA was still unlawful,” an Alliance Defending Freedom attorney told The Daily Signal – potentially meaning any positive policy change might last just a few months before being turned back by a Democrat president in 2029.

Further, abortion pills’ safety level for women is irrelevant to the 1873 Comstock Act, which makes it illegal for the U.S. Postal Service and other common carriers to deliver any “article, instrument, substance, drug, medicine, or thing which is advertised or described in a manner calculated to lead another to use or apply it for producing abortion.” The Biden Justice Department’s Office of Legal Counsel (OLC) declared at the end of 2022 that Comstock would not be enforced, and Trump decided in the 2024 campaign he would not restore it.

Mail-order abortion pills have become the abortion lobby’s most potent tool for circumventing these laws and preserving “choice” without Roe v. Wade. The latest data from the pro-abortion Guttmacher Institute found 1,125,930 clinical abortions in 2025, a slight increase from 2024, that Guttmacher attributed in large part to abortion pills. Planned Parenthood’s 2024-2025 annual report boasts it alone committed 434,450 abortions, a record number for the organization and 8 percent more than the previous year.

Yet completely disconnecting the pills from medical supervision magnifies their already-established risks.

Pro-lifers point to an April 2025 analysis by the Ethics and Public Policy Center that concluded almost 11 percent of women suffer sepsis, infection, hemorrhaging, or other major conditions after taking mifepristone, according to insurance data, plus similar findings by the Restoration of America Foundation, as part of a “growing body of evidence indicating that the health risks associated with mifepristone abortions are severe, widespread, and significantly underreported.”

1 Comments

  1. Loading...